Neuralink Explained: What It Builds and Whether You Can Invest

TL;DR
– Neuralink is a private company. It is not listed on any stock exchange, so there is no Neuralink stock for the public to buy.
– It builds a brain-computer interface (BCI). A small implant reads signals from the brain so a person with paralysis can control a computer cursor or keyboard by thinking about movement.
– Human trials started in 2024. The US FDA cleared a first-in-human study in May 2023, and the first person received the implant in January 2024.
– Neuralink is not the only player. Blackrock Neurotech’s Utah Array has been implanted in people since 2004, and Synchron places its device through a blood vessel instead of open brain surgery.
– The open questions are medical and ethical. Long-term safety, what happens when a device stops working, and who controls brain data are still being worked out.

Contents
1. Can you buy Neuralink stock
2. What a brain-computer interface is
3. What Neuralink’s device does
4. Regulatory milestones so far
5. Other BCI companies
6. Medical and ethical questions
7. FAQ

Most people who search for “Neuralink stock” want a short answer, so here it is first: you cannot buy it on a stock exchange. The more interesting question is what the company actually builds, how far its human trials have come, and what problems brain implants still have to solve. This article covers all three in plain language.

Can you buy Neuralink stock

No. Neuralink is a privately held company and is not listed on any stock exchange. It funds itself through private venture rounds, the latest reported by TechCrunch in June 2025, so there is no public share price.

Like most startups, it raises money privately from venture capital firms. In June 2025, TechCrunch reported that Neuralink “closed a $650 million funding round,” with investors that included ARK Invest, Founders Fund, Sequoia Capital and Thrive Capital. That is how private companies are funded. It is not a door open to ordinary investors.

Two practical warnings. First, any website or message offering “Neuralink shares” to the general public deserves heavy suspicion, because the company has not offered shares to the public. Second, older articles that predicted a listing in 2022 or 2023 were wrong; those dates came and went. If Neuralink ever lists, that will be announced through official filings, not through ads.

What a brain-computer interface is

A brain-computer interface is a system that records electrical activity from the brain and turns it into commands a computer can follow. When you intend to move your hand, neurons in the motor cortex fire in recognisable patterns. Even when a spinal cord injury stops that signal from reaching the hand, the patterns in the brain can still be there. A BCI picks them up and translates them into, say, cursor movement.

The decoding part is where AI comes in. The software has to learn each person’s signals, and it keeps adjusting over time. If you want the wider context of where this sits among other advanced technologies, see our explainer on what counts as high tech.

What Neuralink’s device does

Neuralink’s implant is called the N1. According to Fierce Biotech, “the device contains several dozen threads that hold more than 1,000 electrodes,” and a “specially designed R1 robot” implants the device.

The current clinical study, called PRIME, is aimed at adults with paralysis of the arms and legs caused by a cervical spinal cord injury or ALS (Fierce Biotech). The goal is practical: let people control a computer again without using their hands.

What participants have done with it, according to company and news reports:
– The first participant has used it to “play video games, browse the internet, post on social media and move a cursor on a laptop” (Reuters via WHBL).
– Neuralink says the technology enabled its second participant “to play video games and use CAD software” (Neuralink).

The bigger claims around Neuralink, such as people merging with AI, come from public statements about long-term ambitions. They are not what the trials test. The trials test whether a paralysed person can safely and reliably use a computer.

Regulatory milestones so far

Medical implants in the US need clearance from the Food and Drug Administration before they can be tested in people. Neuralink’s path was not smooth.

A note on “breakthrough” status: it sounds like approval, but it is not. It is an FDA programme “intended to speed up development, assessment, and review processes for experimental technologies” (TechCrunch). The device is still experimental and not available as a regular treatment.

Other BCI companies

Neuralink gets most of the headlines, but it did not invent the field, and it is not the only company with people implanted.

The trade-off is roughly the same across the field. Electrodes inside brain tissue capture more detailed signals but need open surgery. Devices in blood vessels avoid opening the skull but sit further from the neurons. Which approach wins, if any single one does, is still an open question.

Blackrock’s history also puts the hype in proportion. According to the company, Matt Nagle, the first person with a Utah Array, used his interface to control an artificial hand a year after his 2004 implant (Blackrock Neurotech). The basic idea has been working in labs for two decades. What is new is the attempt to make it wireless, smaller and usable outside a research setting.

Medical and ethical questions

Brain implants raise questions that ordinary gadgets do not.

Safety over years, not months. Neuralink says it has a record of “zero serious device-related adverse events” (Reuters via WHBL). That is encouraging, but the trials are young. The thread retraction in the first patient shows that the brain is not a static place to put hardware.

Removal and upgrades. Safe removal was one of the issues the FDA reportedly raised in 2022 (TechSpot). If a better model comes out, or the company changes direction, what happens to the people who already have the old one?

Brain data and privacy. Neural signals can reveal far more than intended movements. UNESCO adopted a global Recommendation on the ethics of neurotechnology, which entered into force on 12 November 2025, noting that neural data “can reveal emotions and reactions, raising concerns about privacy and consent” (UNESCO UK). It also warns against tools that monitor or profile employees.

Consent and expectations. Trial participants have severe paralysis and limited alternatives. That makes clear, honest information about risks and realistic benefits more important, not less. Medical progress here is real, but it is slow and measured in individual patients, not in headlines.

FAQ

About the Author

Vyara Stefcheva

Vyara Stefcheva is the founder and editor of Egorithms and an independent marketing expert. She follows how technology, AI and algorithms change the way people find, choose and buy, and writes about what that means for businesses and for the people who use them.

She has spent her career building marketing and business strategies for more than 300 brands across three continents. She built and exited a marketing agency and now works independently. She has taught more than 20,000 people through lectures, courses and corporate training, and speaks at conferences about AI and the future of the internet.

On her YouTube channel she tests new AI and marketing tools as they launch and gives each an independent verdict: adopt, watch or ignore.

See author's posts